At the time of writing, CytomX Therapeutics Inc [CTMX] stock is trading at $2.11, up 2.43%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CTMX shares have gain 7.65% over the last week, with a monthly amount drifted -0.47%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
CytomX Therapeutics Inc [NASDAQ: CTMX] stock has seen the most recent analyst activity on September 22, 2025, when Cantor Fitzgerald initiated its Overweight rating and assigned the stock a price target of $6. On July 31, 2025, Oppenheimer initiated with a Outperform rating and assigned a price target of $7 on the stock. H.C. Wainwright upgraded its rating to a Buy but stick to its price target of $5 on May 15, 2025. Piper Sandler upgraded its rating to Overweight for this stock on May 28, 2024, and upped its price target to $3.50. In a note dated May 09, 2024, Wedbush upgraded an Outperform rating on this stock but restated the target price of $8.
For the past year, the stock price of CytomX Therapeutics Inc fluctuated between $0.40 and $3.10. Currently, Wall Street analysts expect the stock to reach $5.25 within the next 12 months. CytomX Therapeutics Inc [NASDAQ: CTMX] shares were valued at $2.11 at the most recent close of the market. An investor can expect a potential return of 148.82% based on the average CTMX price forecast.
Analyzing the CTMX fundamentals
According to CytomX Therapeutics Inc [NASDAQ:CTMX], the company’s sales were 141.10M for trailing twelve months, which represents an -25.71% plunge. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at 0.31%, Pretax Profit Margin comes in at 0.34%, and Net Profit Margin reading is 0.34%. To continue investigating profitability, this company’s Return on Assets is posted at 0.27, Equity is 1.59 and Total Capital is 0.32. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.03 points at the first support level, and at 1.94 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.17, and for the 2nd resistance point, it is at 2.22.
Ratios To Look Out For
It is important to note that CytomX Therapeutics Inc [NASDAQ:CTMX] has a current ratio of 4.20. In addition, the Quick Ratio stands at 4.20 and the Cash Ratio stands at 1.25. Considering the valuation of this stock, the price to sales ratio is 2.47, the price to book ratio is 2.90 and price to earnings (TTM) ratio is 3.69.
Transactions by insiders
Recent insider trading involved Ogden Christopher, Chief Financial Officer, that happened on Jun 16 ’25 when 10614.0 shares were sold. Chief Financial Officer, Ogden Christopher completed a deal on Jun 13 ’25 to sell 1641.0 shares. Meanwhile, SVP, Chief Scientific Officer BELVIN MARCIA sold 13884.0 shares on Jun 16 ’25.
